alendronate-sodium and Osteoporosis

In this work, we found that 14-deoxy-11,12-didehydroandrographolide (2), a derivative of andrographolide (AP, 1), had greatly reduced cytotoxicity compared with AP and exhibited moderate anti-osteoclastogenesis activity. Thirty compounds were synthesized by introducing anti-osteoporosis chemotypes at C-19 of 2. Six of them exhibited stronger inhibition of osteoclastogenesis than AP. Of note, compound 12g displayed the most potent activity with IC

Topics: Animals; Bone Resorption; Cell Differentiation; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Female; Mice; Mice, Inbred C57BL; Molecular Structure; Osteoclasts; Osteogenesis; Osteoporosis; RAW 264.7 Cells; Structure-Activity Relationship

Glucosamine hydrochloride (GAH), one of the most basic and important derivatives of chitin, is obtained by hydrolysis of chitin in concentrated hydrochloric acid. At present, little is known about how GAH functions in skeletal development. In this report, we demonstrate that GAH, extracted from the cell wall of

Topics: Agaricus; Animals; Bone and Bones; Bone Morphogenetic Proteins; Disease Models, Animal; Glucosamine; Larva; Osteoporosis; Regeneration; Signal Transduction; Skeleton; Zebrafish

In this paper, we applied a chemotype-assembly approach for ligand-based drug discovery (LBDD) to discover novel anti-osteoporosis leads. With this new approach, we identified 12 chemotypes and derived 18 major chemotype assembly rules from 245 known anti-osteoporosis compounds. Then, we selected 19 compounds from an in-house compound library using chemotype-assembly approach for anti-osteoporosis assays, which resulted in 13 hits. Based on structural features in these 13 compounds, we synthesized 50 possible anti-osteoporosis compounds from the anti-osteoporosis chemotypes by means of click chemistry techniques and discovered a compound (10a, IC

Topics: Animals; Bone Density; Bone Resorption; Drug Discovery; Female; Femur; High-Throughput Screening Assays; Ligands; Osteoblasts; Osteoporosis; Rats; Rats, Sprague-Dawley

As human beings live longer, age-related diseases such as osteoporosis will become more prevalent. Intolerant side effects and poor responses to current treatments are observed. Therefore, novel effective therapeutic agents are greatly needed. Here, pyrazole derivatives were designed and synthesized, and their osteoclastogenesis inhibitory effects both in vitro and in vivo were evaluated. The most promising compound 13 with a 2-(dimethylamino)ethyl group inhibited markedly in vitro osteoclastogenesis as well as the bone resorption activity of osteoclasts. Compound 13 affected osteoclast's early proliferation and differentiation more than later fusion and maturation stages. In ovariectomized (OVX) mice, compound 13 can inhibit the loss of trabecular bone volume, trabecular bone number, and trabecular thickness. Moreover, compound 13 can antagonize OVX-induced reduction of serum bone resorption marker and then compensatory increase of the bone formation marker. To sum up, compound 13 has high potential to be developed into a novel therapeutic agent for treating osteoporosis in the future.

Topics: Animals; Bone Density; Bone Resorption; Cell Differentiation; Cells, Cultured; Female; Humans; Male; Mice; NF-kappa B; Osteoclasts; Osteoporosis; Ovariectomy; Pyrazoles; RANK Ligand; Rats, Sprague-Dawley; Tibia